Axitinib modulates hypoxia-induced bloodretina barrier permeability and expression of growth factors

Growth Factors

Volumn 30, Issue 1, 2012, Pages 49-61

  Kernt, Marcus ^a   Thiele, Sarah ^a   Liegl, Raffael G ^a   Kernt, Barbara ^a   Eibl, Kirsten ^a   Haritoglou, Christos ^a   Ulbig, Michael W ^a   Kampik, Anselm ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Axitinib; Bevacizumab; Diabetic macular edema; Diabetic retinopathy; Growth factors; Multikinase inhibitors; Pazopanib; VEGF

Indexed keywords

AXITINIB; GROWTH FACTOR; MESSENGER RNA; OCCLUDIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN ZO1; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD RETINA BARRIER; CELL VIABILITY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; BLOOD-RETINAL BARRIER; CELL HYPOXIA; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CELLS, CULTURED; DIABETIC RETINOPATHY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; INDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACULAR EDEMA; MIDDLE AGED; PIGMENT EPITHELIUM OF EYE; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84855830605     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.639300     Document Type: Article

References (39)

1. Ablonczy Z, Crosson CE. 2007. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 85(6):762-771. (Pubitemid 350166363)
2. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. 1995. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 92(23):10457-10461.
3. AntonettiDA, Barber AJ, Khin S, Lieth E, Tarbell JM, GardnerTW. 1998. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47(12):1953-1959. (Pubitemid 28549205)
4. Bailey TA, Kanuga N, Romero IA, Greenwood J, Luthert PJ, Cheetham ME. 2004. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 45(2):675-684. (Pubitemid 38140530)
5. Betsholtz C, Karlsson L, Lindahl P. 2001. Developmental roles of platelet-derived growth factors. Bioessays 23(6):494-507. (Pubitemid 32575610)
6. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, et al. 1997. Vascular permeability factor/vascular endothelial growth factor: A multifunctional angiogenic cytokine. EXS 79: 233-269.
7. Chappelow AV, Kaiser PK. 2008. Neovascular age-related macular degeneration: Potential therapies. Drugs 68(8):1029-1036. (Pubitemid 351693673)
8. Cui J, Lei H, Samad A, Basavanthappa S, Maberley D, Matsubara J, et al. 2009. PDGF receptors are activated in human epiretinal membranes. Exp Eye Res 88(3):438-444.
9. Cunha-Vaz JG, Shakib M, Ashton N. 1966. Studies on the permeability of the blood-retinal barrier. I. On the existence, development, and site of a blood-retinal barrier. Br J Ophthalmol 50(8):441-453.
10. Ehrlich R, Harris A, Kheradiya NS, Winston DM, Ciulla TA, Wirostko B. 2008. Age-related macular degeneration and the aging eye. Clin Interv Aging 3(3):473-482.
11. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. 2010. Diabetic macular oedema: Physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol 88(3):279-291.
12. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. 2004. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 18(2):338-340.
13. Grisanti S, Tatar O. 2008. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27(4):372-390.
14. Haines JL, Schnetz-Boutaud N, Schmidt S, Scott WK, Agarwal A, Postel EA, et al. 2006. Functional candidate genes in age-related macular degeneration: Significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 47(1):329-335. (Pubitemid 46780832)
15. Hollborn M, Bringmann A, Faude F, Wiedemann P, Kohen L. 2006. Signaling pathways involved in PDGF-evoked cellular responses in human RPE cells. Biochem Biophys Res Commun 344(3):912-919.
16. Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, et al. 2006. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168(6):2036-2053. (Pubitemid 43825322)
17. Kelly RJ, Rixe O. 2010. Axitinib (AG-013736). Recent Results Cancer Res 184:33-44.
18. Kernt M, Staehler M, Stief C, Kampik A, Neubauer AS. 2008. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol 86(4): 456-458.
19. Kernt M, Neubauer AS, Liegl R, Eibl KH, Alge CS, Lackerbauer CA, Ulbig MW, Kampik A. 2009. Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract Refract Surg 35(2):354-362.
20. Kernt M, Neubauer AS, Liegl RG, Hirneiss C, Alge CS, Wolf A, Ulbig MW, Kampik A. 2010. Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF. Br J Ophthalmol 94(11):1533-1539.
21. Kevil CG, Okayama N, Trocha SD, Kalogeris TJ, Coe LL, Specian RD, Davis CP, Alexander JS. 1998. Expression of zonula occludens and adherens junctional proteins in human venous and arterial endothelial cells: Role of occludin in endothelial solute barriers. Microcirculation 5(2-3):197-210. (Pubitemid 128647895)
22. Miyamoto N, de Kozak Y, Jeanny JC, Glotin A, Mascarelli F, Massin P, BenEzra D, Behar-Cohen F. 2007. Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: Potential implication in the pathogenesis of diabetic retinopathy. Diabetologia 50(2):461-470.
23. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2):55-63. (Pubitemid 14203433)
24. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. 2007. Understanding the biology of angiogenesis: Review of the most important molecular mechanisms. Blood Cells Mol Dis 39(2): 212-220. (Pubitemid 47126926)
25. Praidou A, Androudi S, Brazitikos P, Karakiulakis G, Papakonstantinou E, Dimitrakos S. 2010. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr Diabetes Rev 6(5):304-312.
26. Robbins SG, Mixon RN, Wilson DJ, Hart CE, Robertson JE, Westra I, Planck SR, Rosenbaum JT, 1994. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 35(10): 3649-3663. (Pubitemid 24337978)
27. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. 2005. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23(24):5474-5483.
28. Schlingemann RO. 2004. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242(1):91-101. (Pubitemid 38208289)
29. Schlingemann RO, Oosterwijk E, Wesseling P, Rietveld FJ, Ruiter DJ. 1996. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol 179(4):436-442. (Pubitemid 26276116)
30. Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. 2010. General pathophysiology of macular edema. Eur J Ophthalmol 21(S6):10-19.
31. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez C. 2006. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2(1):71-98. (Pubitemid 44082952)
32. Simo R, VillarroelM, Corraliza L, Hernandez C, Garcia-RamirezM. 2010. The retinal pigment epithelium: Something more than a constituent of the blood-retinal barrier - implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol 2010: 190724.
33. Spoerri PE, Afzal A, Li Calzi S, Shaw LC, Cai J, Pan H, et al. 2006. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis 12:32-42. (Pubitemid 43072829)
34. Takahashi K, Saishin Y, Saishin Y, King AG, Levin R, Campochiaro PA. 2009. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 127(4):494-499.
35. The DCCT Research Group 1991. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. Am J Med 90(4):450-459.
36. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. 2000. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60(2):203-212. (Pubitemid 30070735)
37. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. 2008. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129-3140.
38. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, GirachA. 2004.Epidemiology of diabetic retinopathy andmacular oedema: A systematic review. Eye (Lond) 18(10):963-983. (Pubitemid 39430033)
39. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. 2003. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22(1):1-29. (Pubitemid 36207453)